|
|
|
|
|
|
|
 Ira Flatow Veteran National Public Radio® (NPR) science correspondent and award winning radio and TV journalist Ira Flatow is the anchor of Talk Of The Nation: Science Friday.® He hosts the show each Friday, bringing NPR listeners a lively, informative discussion on science and technology. He has shared his enthusiasm for all things science with public radio listeners for more than 30 years. As NPR's science correspondent from 1971 to 1986, Flatow covered science, health, technology and the environment; his career found him reporting from the Kennedy Space Center, Three Mile Island, Antarctica and the South Pole. In one NPR report, Flatow took former All Things Considered® host Susan Stamberg into a closet to crunch Wint-O-Green Lifesavers in the dark. Conducting the demonstration on the radio from inside the closet, Flatow proved that the Lifesavers do indeed spark when chewed. Before joining NPR, Flatow was News Director at WBFO-FM/Buffalo, New York(1971). He began reporting at the station while studying for his engineering degree at State University of New York in Buffalo. His numerous network TV credits include six years as host and writer for the Emmy-award-winning Newton's Apple on PBS (1982-87); science reporter for CBS This Morning, and PM Magazine (Westinghouse). Flatow has worked for a variety of cable networks, including CNBC, Nickelodeon, The Learning Channel, The Discovery Channel and The History Channel. He recently wrote, produced and hosted the award winning PBS documentary Transistorized! about the history of the transistor. He has talked science on many TV talk shows including Merv Griffin, Today, Charlie Rose, and Oprah. In print, Ira has authored articles for various magazines ranging from Woman's Day to ESPN Magazine to American Lawyer. His commentary has appeared in The Los Angeles Times, and Current newspapers. His most recent book is entitled They All Laughed ... From Light Bulbs to Lasers: The Fascinating Stories Behind the Great Inventions That Have Changed Our Lives (HarperCollins, New York). It followed on the heels of Rainbows, Curve Balls and Other Wonders of the Natural World Explained. His recent honors include: Elizabeth Wood Writing Award (2001), the AAAS Journalism award (2000), Brady Washburn Award (2000) , the Carl Sagan Award (1999). He is also a board member of the National Association of Science Writers.  Ed Harlow, Ph.D. A renowned cancer researcher, Dr. Harlow is Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology, Scientific Director of the Massachusetts General Hospital Cancer Center, and Dean for Research at Harvard Medical School. Dr. Harlow received a B.S. and a M.S. in 1974 and 1978 from the University of Oklahoma and his Ph.D. in 1982 from the Imperial Cancer Research Fund Laboratories in London. Among Dr. Harlow’s many awards are the Wallace P. Rowe Award for Excellence in Virologic Research (1989); Milken Family Medical Foundation Cancer Research Award (1989); Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research (1991); American Cancer Society Research Professor; National Academy of Sciences (elected 1993); Alfred P. Sloan Jr. Prize, General Motors Cancer Research Foundation (1995); American Academy of Arts and Sciences (elected 1996); Dickson Prize in Medicine, University of Pittsburgh (1996); Lila Gruber Cancer Research Award, American Association of Dermatology (1997); Institute of Medicine (elected 1999). Dr. Harlow sits on the scientific advisory boards of numerous institutions and companies, including the William Guy Forbeck Foundation; Children’s Hospital, Boston; the Foundation for Advanced Cancer Studies, Onyx Pharmaceuticals Inc., and Genomics Collaborative Inc. He is a member of the selection committee of several important awards, notably the Lasker Award Committee and General Motors Cancer Research Award Assembly. He is also a trustee of Cold Spring Harbor Laboratory in New York. Dr. Harlow's research interests are in how mammalian cells initiate and regulate cell division. He is the author of many papers focusing on tumor suppressor gene products and mammalian cell cycle control.  Steve Holtzman Steven H. Holtzman is a founder and the President and Chief Executive Officer of Infinity Pharmaceuticals, Inc., a start-up drug discovery company. From early 1994 through mid-2001, Mr. Holtzman served as the Chief Business Officer of Millennium Pharmaceuticals, Inc. Since its founding in 1993, Millennium has grown to over 1,500 employees and is ranked among the top ten companies in the biotechnology industry in market and revenues. Millennium is a pioneer and leader in the identification of the genetic basis of common human diseases and the use of such information to develop therapeutic and diagnostic products directed to the cause, not merely the symptoms, of disease. Prior to joining Millennium, from 1986-1994, Mr. Holtzman was a founder of DNX Corporation, the first commercial enterprise devoted to the development of biomedical and pharmaceutical applications of transgenic animal technology. DNX pioneered the development of genetically engineered laboratory animals as better models of human disease and the development of genetically engineered pigs as a potential source of organs for transplantation to humans. In 1995, Mr. Holtzman co-founded and has since been the Co-chair of the Biotechnology Industry Organization (BIO) Bioethics Committee. In 1998, he served as a member of the Working Group of the Advisory Committee to the Director of the NIH on Access to Research Tools. In 1996, he was appointed by President Clinton as the sole individual from the pharmaceutical or biotechnology industry to serve on the National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences. In late-1999, he was asked to serve a second term on the Commission. Since 1999, he has served as a Trustee of the Hastings Center for Bioethics. Mr. Holtzman received his B.A. in Philosophy from Michigan State University and his B.Phil. graduate degree in Philosophy from Oxford University.  Steven Hyman Steven E. Hyman, M.D., assumed the role of Provost of Harvard University in December of 2001 and also serves as Professor of Neurobiology at Harvard Medical School. A leading scholar at the intersection of molecular neuroscience, molecular biology, and psychiatry, Dr. Hyman returns to Harvard after serving as the Director of the National Institute of Mental Health (NIMH) from 1996 to 2001. Hyman's tenure at NIMH was marked by intensified efforts to integrate molecular biology, genetics, neuroscience, and behavioral science to improve our understanding of mental illness and mental health.
Dr. Hyman graduated from Yale College in 1974 with a degree in philosophy and the humanities. In 1976, as a Mellon fellow in philosophy of science, he received BA and MA degrees from the University of Cambridge. Four years later he received his MD from Harvard Medical School. Following an internship in medicine at Massachusetts General Hospital (MGH), a residency in psychiatry at McLean Hospital, and a clinical fellowship in neurology at MGH, he was postdoctoral fellow at Harvard in molecular biology.
Dr. Hyman was Professor of Psychiatry at Harvard Medical School and Director of Psychiatry Research at Massachusetts General Hospital from 1992 until he left for NIMH in 1996. His laboratory focused on mechanisms by which the neurotransmitter dopamine produced long-term changes in brain function by the regulating the expression of genes. This research was relevant both to understanding addiction, and to understanding how therapeutic psychotropic drugs produced their beneficial effects.
He also taught neurobiology at Harvard Medical School both to medical and graduate students and was the first faculty Director of Harvard University's Interfaculty Initiative in Mind, Brain, and Behavior from 1994 to 1996.
Among his distinctions, Dr. Hyman is a member of the Institute of Medicine of the National Academy of Sciences. He also has received awards for public service from the U. S. Government and from patient advocacy groups such as the National Alliance for the Mentally Ill and the National Mental Health Association. Across the country and over the world, he has lectured on topics ranging from genes, brain, and behavior to the stigma of mental illness.
Dr. Hyman is a member of the Society for Neuroscience, the American College of Neuropsychopharmacology and the American College of Psychiatrists. He has served on scientific advisory boards nationally and internationally including the Howard Hughes Medical Institute, the Riken Brain Sciences Institute in Japan, and the Max Planck Institute for Psychiatry in Germany.
Christian Ketels, Ph.D. Christian H. M. Ketels is the Principal Associate at the Institute for Strategy and Competitiveness. As Head of Research and "Chief-of-Staff" his responsibilities stretch across the full breadth of the Institute’s intellectual agenda. His own research interests focus on the relationship between company strategy and location and on competitiveness at different geographic levels, especially in Europe. Christian received his PhD (Economics) from the London School of Economics (LSE) where he developed microeconomic models analyzing the relationship between international competition and firm efficiency. Christian worked as a strategy consultant for Monitor Company from 1997 to 2000 in the UK, Germany, and Scandinavia, and was part of a team that founded Cell Strategy (now part of Adcore AB), a Swedish-based Internet Strategy Consultancy, in 2000. He continues to have a keen interest in politics of his home country Germany where he was member of the CDU Internet-Commission in 2000/01. 
Marc
Kirschner, Ph.D. Marc W. Kirschner, Ph.D., founding chair of the Department of Cell Biology and Carl W. Walter Professor of Cell Biology at Harvard Medical School, co-founded Harvard’s Institute for Chemistry and Cell Biology which was established in fall 1998. He and John Gerhart are co-authors of Cells, Embryos, and Evolution (Blackwell, 1997). Dr. Kirschner was elected Foreign Member of the Royal Society of London and as a Foreign Member of the Academia Europaea in 1999. He was the 2001 recipient of the William C. Rose Award, presented by the American Society for Biochemistry and Molecular Biology. In October, he received a 2001 International Award by the Gairdner Foundation of Toronto. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences, and has served on the Advisory Committee to the Director of the National Institutes of Health and as President of the American Society for Cell Biology. Dr. Kirschner’s laboratory investigates three broad, diverse areas: regulation of the cell cycle, the role of cytoskeleton in cell morphogenesis, and mechanisms of establishing the basic vertebrate body plan. In 1993, Dr. Kirschner arrived at Harvard Medical School from the University of California, San Francisco, where he had served on the faculty as Professor for fifteen years. Dr. Kirschner graduated from Northwestern University in 1966 and received his Ph.D. from the University of California, Berkeley in 1971. Following postdoctoral research at Berkeley and at the University of Oxford, he was appointed an Assistant Professor at Princeton University in 1972. 
Joseph
Boyd Martin, M.D., Ph.D. Joseph B. Martin is Dean of the Harvard Faculty of Medicine. Prior to his appointment to his current position in 1997, Dr. Martin served as chancellor of the University of California, San Francisco and, earlier, as dean of its school of medicine. As a member of the Harvard medical community in the late 1970s and early 1980s, he served as the chief of the neurology service at Massachusetts General Hospital. An internationally recognized leader in the field of neurological sciences, Dr. Martin's research has focused on hypothalamic regulation of pituitary hormone secretions and on application of neurochemical molecular genetics in order to better understand the causes of neurological and neuro-degenerative disease. In 1980, Dr. Martin established the National Institutes of Health-sponsored Huntington Disease Center Without Walls. Early work at the center led to a breakthrough in identifying a genetic marker near the gene for Huntington's disease—a discovery recently culminating in the identification of the gene for that disease. During his tenure as dean of the UCSF School of Medicine, Dr. Martin established the W.M. Keck Foundation for Integrative Neurosciences, dedicated to combining studies of the brain and behavior, and the Gladstone Institute for Virology and Immunology, committed to AIDS research. Born in Alberta, Canada, Dr. Martin received his premedical and medical education at the University of Alberta, earning his medical degree in 1962. He completed a residency in neurology in 1966 and a fellowship in neuropathology in 1967 at Case Western Reserve University and earned his doctoral degree in anatomy from the University of Rochester in 1971. 
Stuart
Schreiber, Ph.D. Stuart Schreiber
is the Morris Loeb Professor at Harvard University, where he is a member
of the Department of Chemistry and Chemical Biology and the Graduate Program
in Biophysics and an associate member of the Department of Molecular and
Cellular Biology. He is an affiliate of the Department of Cell Biology
and a member of the Graduate Program in Immunology at Harvard Medical
School and Co-director of the Harvard Institute of Chemistry and Cell
Biology. He received his Ph.D. degree in organic chemistry from Harvard
University, working in the laboratories of Robert Woodward and Yoshito
Kishi. Dr. Schreiber is a member of the National Academy of Sciences.
His recent honors include the William H. Nichols Medal and the Chiron
Corporation Biotechnology Research Award from the American Academy of
Microbiology. Click here
for more information on Stuart Schreiber and his research interests.  Martin B. Silverstein, M.D. As a senior vice president of The Boston Consulting Group (BCG) and head of the firm’s health care practice in North America, Marty Silverstein works closely with many of the leading global pharmaceutical and biotechnology companies. His focus is on helping these companies develop and commercialize new therapies. He has also been integrally involved in many of the recent major biotech and pharmaceutical mergers. His academic background includes both business and medicine. He holds an MD from the Yale University School of Medicine and an MBA from Harvard Business School. He is board-certified in internal medicine, having completed a residency at Boston’s Beth Israel Hospital, a major Harvard Medical School teaching hospital. Before joining BCG he worked as a physician in private and corporate practice and as a senior scientist and project manager at the Health Data Institute. He earned a BA summa cum laude in economics and natural sciences from the University of Pennsylvania. Of interest and importance to the HMS community is a report that BCG is preparing jointly with the Massachusetts Biotechnology Council. The report articulates a vision for the Massachusetts biotechnology industry and broader life-sciences economic cluster. It identifies the main challenges and presents a detailed call-to-action for Massachusetts’ policy makers and for its life sciences community. Dr. Silverstein is one of the two principal authors of the report. Titled “MassBiotech 2010: Achieving Global Leadership in the Life-Sciences Economy,” it is scheduled for release in mid-December of this year. The Boston Consulting Group is one of the world’s leading management consulting firms, best known for its innovations in strategic business thinking. The firm’s health care practice serves leading companies across the health care value chain. It is recognized for its pioneering work on disease management and the changing structure of the health care delivery system in the 1980s and early 1990s. Today BCG is engaged in understanding the impact of new technologies, such as genomics and bioinformatics, on the productivity of the biopharmaceutical industry. 
Lawrence
H. Summers, Ph.D. Lawrence H. Summers took office as the 27th president of Harvard University on July 1, 2001. An eminent scholar and admired public servant, Mr. Summers is the former Nathaniel Ropes Professor of Political Economy at Harvard, and in the past decade served in a series of senior public policy positions, most recently as secretary of the treasury of the United States. Born in New Haven, Connecticut, Mr. Summers spent most of his childhood in Penn Valley, Pennsylvania, a suburb of Philadelphia. He received his bachelor of science degree from the Massachusetts Institute of Technology in 1975, and PhD in economics from Harvard University in 1982. In 1991 Mr.
Summers was appointed the vice president of development economics and
chief economist of the World Bank. In 1993, he was named as the nation's
undersecretary of the treasury for international affairs. In 1995, then
Secretary Robert E. Rubin AB '60 promoted Mr. Summers to the department's
number-two post, deputy secretary of the treasury, in which he played
a central role in a broad array of economic, financial, and tax matters,
both international and domestic. During this time, he worked closely with
Secretary Rubin and Alan Greenspan LLD '99 (hon.), chairman of the Federal
Reserve System, in crafting government policy responses to financial crises
in major developing countries. On July 2, 1999, Mr. Summers was confirmed
by the Senate as secretary of the treasury. In that capacity, he served
as the principal economic adviser to the President and as the chief financial
officer of the U.S. government, presiding over a federal department comprising
some two dozen distinct bureaus and offices. 
Henri Termeer Born in Tilburg, Holland, Henri Termeer studied economics at the University of Rotterdam and earned an MBA from the Darden School, at the University of Virginia. Having served as both president and CEO of Genzyme Corporation, Mr. Termeer was appointed chairman of the company in 1988. Under his leadership, Genzyme has grown from a small entrepreneurial venture into one of the world’s top biotechnology companies. His innovative approaches have earned Genzyme the Laguna Niguel Best of Biotech Award in 1991 and 1994, as well as the Laguna Niguel Hall of Fame Award in 1997. Mr. Termeer serves as a board member for a number of biotechnology corporations, including Genzyme Transgenics Corporation, ABIOMED, AutoImmune, Inc., GelTex Pharmaceuticals, and Diacrin, Inc., and is a trustee for both Hambrecht & Quist Health Care Investors and Hambrecht & Quist Life Sciences. He is also a trustee for the Darden Graduate School of Business Administration, a director of the Massachusetts Cystic Fibrosis Foundation, a trustee and vicechairman of the Boston Museum of Science, and a member of the Massachusetts Governor’s Council on Economic Growth and Technology. He sits on two boards at the Massachusetts Institute of Technology serving the Department of Biology Visiting Committee, as well as the Dean’s Advisory Council for the Sloan School of Management. In February 2000, Mr. Termeer was honored by the Genetic Disease Foundation at the Mount Sinai Medical Center with its Humanitarian of the Year award. In 1997, he received the honor of Humanitarian of the Year by The Cardinal Cushing School for Exceptional Children. In 1999, he was recognized by the Biomedical Science Careers Project, a collaborative effort of Harvard Medical School, the New England Board of Higher Education, and the Massachusetts Medical Society, for his leadership in supporting the education of minorities. In 1995, he was honored by the Anti-Defamation League’s New England Region with the Torch of Liberty Award for his leadership in human rights and for promoting understanding among people of diverse backgrounds.
|